AGP
Artia Global Partners Portfolio holdings
AUM
$389M
This Quarter Return
+15.32%
1 Year Return
+34.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$341M
AUM Growth
+$341M
(+38%)
Cap. Flow
+$72M
Cap. Flow
% of AUM
21.12%
Top 10 Holdings %
Top 10 Hldgs %
81.4%
Holding
43
New
8
Increased
6
Reduced
8
Closed
9
Top Buys
| 1 |
Eli Lilly
LLY
|
$78.4M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$18M |
| 3 |
Boston Scientific
BSX
|
$13.1M |
| 4 |
Insmed
INSM
|
$11.5M |
| 5 |
Quest Diagnostics
DGX
|
$9.6M |
Top Sells
| 1 |
Novo Nordisk
NVO
|
$17.2M |
| 2 |
Vaxcyte
PCVX
|
$13.3M |
| 3 |
Nuvalent
NUVL
|
$8.04M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$7.51M |
| 5 |
Revolution Medicines
RVMD
|
$6.36M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$657B
| $78.4M | 19.84% |
+94,887
| New | +$78.4M |
|
2
Soleno Therapeutics
SLNO
$3.6B
| $35.6M | 9.01% |
498,473
+4,049
| +0.8% | +$289K |
|
|
VRNA
3
Verona Pharma
VRNA
$9.16B
| $34.2M | 8.65% |
538,488
+283,170
| +111% | +$18M |
|
|
ITCI
4
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $29M | 7.34% |
219,719
| – | – |
|
|
5
Insmed
INSM
$28.8B
| $24.3M | 6.15% |
318,239
+150,300
| +89% | +$11.5M |
|
6
Merus
MRUS
$4.98B
| $17.9M | 4.52% |
424,640
-39,200
| -8% | -$1.65M |
|
7
Protagonist Therapeutics
PTGX
$3.67B
| $16.1M | 4.09% |
333,851
+40,000
| +14% | +$1.93M |
|
8
Arcellx
ACLX
$3.85B
| $15M | 3.8% |
229,085
-700
| -0.3% | -$45.9K |
|
9
AstraZeneca
AZN
$248B
| $14M | 3.55% |
190,752
| – | – |
|
|
10
Boston Scientific
BSX
$156B
| $13.1M | 3.31% |
+129,700
| New | +$13.1M |
|
|
11
Quest Diagnostics
DGX
$20.3B
| $9.6M | 2.43% |
+56,717
| New | +$9.6M |
|
|
12
Alnylam Pharmaceuticals
ALNY
$58.5B
| $7.72M | 1.95% |
28,600
-27,800
| -49% | -$7.51M |
|
13
argenx
ARGX
$43.6B
| $6.69M | 1.69% |
11,311
| – | – |
|
|
14
Nuvalent
NUVL
$5.52B
| $6.44M | 1.63% |
90,745
-113,300
| -56% | -$8.04M |
|
15
Scholar Rock
SRRK
$3.14B
| $5.54M | 1.4% |
+172,185
| New | +$5.54M |
|
|
16
Revolution Medicines
RVMD
$7.1B
| $3.68M | 0.93% |
104,190
-180,000
| -63% | -$6.36M |
|
17
Rhythm Pharmaceuticals
RYTM
$6.85B
| $2.65M | 0.67% |
50,000
| – | – |
|
|
SWTX
18
DELISTED
SpringWorks Therapeutics
SWTX
| $2.38M | 0.6% |
53,930
| – | – |
|
19
Viking Therapeutics
VKTX
$3.04B
| $2.18M | 0.55% |
90,279
| – | – |
|
20
Viridian Therapeutics
VRDN
$1.5B
| $2.16M | 0.55% |
160,000
+60,000
| +60% | +$809K |
|
21
TG Therapeutics
TGTX
$4.65B
| $2.15M | 0.54% |
54,515
| – | – |
|
22
Intuitive Surgical
ISRG
$170B
| $1.73M | 0.44% |
+3,500
| New | +$1.73M |
|
23
EyePoint Pharmaceuticals
EYPT
$797M
| $1.72M | 0.43% |
316,700
+100,000
| +46% | +$542K |
|
24
Neurocrine Biosciences
NBIX
$13.8B
| $1.63M | 0.41% |
14,700
-30,300
| -67% | -$3.35M |
|
25
United Therapeutics
UTHR
$13.8B
| $1.54M | 0.39% |
+5,000
| New | +$1.54M |
|